Founded at the Abramson Cancer Center at the University of Pennsylvania

Use of the Nicotine Metabolite Ratio as a Genetically Informed Biomarker of Response to Nicotine Patch or Varenicline for Smoking Cessation: A Randomised, Double-Blind Placebo-Controlled Trial

Use of the Nicotine Metabolite Ratio as a Genetically Informed Biomarker of Response to Nicotine Patch or Varenicline for Smoking Cessation: A Randomised, Double-Blind Placebo-Controlled Trial

The Lancet Respiratory Medicine | 2015

Caryn Lerman; Robert A. Schnoll; Larry W. Hawk; Paul Cinciripini; Tony P. George; E. Paul Wileyto; Gary E. Swan; Neal L. Benowitz; Daniel F. Heitjan; Rachel F. Tyndale